TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that the Régie de l'Assurance Maladie du Québec (RAMQ) has added JUXTAPID™ (lomitapide) capsules for the treatment of homozygous familial hypercholesterolemia (HoFH) to its formulary effective November 20, 2015. The listing was based on a recommendation from l'Institut National d'Excellence en Santé et en Services Sociaux (INESSS) and is subject to a Listing Agreement between the Quebec Minister of Health and...
↧